Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 481-494

  López Labrador, F Xavier ^a,b,c   Moya, Andrés ^b,c   Gonzàlez Candelas, Fernando ^b,c  

^a Generalitat Valenciana   (United Kingdom)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CILUPREVIR; ITMN 191; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; PROTEINASE INHIBITOR; SCH 6; TELAPREVIR;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MAPPING; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CARBAMATES; CARRIER PROTEINS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; MACROCYCLIC COMPOUNDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PROLINE; PROTEASE INHIBITORS; QUINOLINES; SEQUENCE ALIGNMENT; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; WORLD HEALTH;

EID: 47649116685     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. World Health Organization. Hepatitis C fact sheet. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:s21-s29.
3. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35:666-678.
4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Micro 2007; 5:453-463.
5. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004; 85:3173-3188.
6. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993; 67:2832-2843.
7. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-189.
8. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN-2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127:1347-1355.
9. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006; 50:1813-1822.
10. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. 28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG-interferon- α-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006; 131:950-951.
11. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013-1020.
12. Bogen SL, Arasappan A, Bennett F, et al. Discovery of SCH446211 (SCH-6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 2006; 49:2750-2757.
13. Liu R, Abid K, Pichardo J, Pazienza V, et al. In vitro antiviral activity of SCH446211 (SCH-6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother 2007; 59:51-58.
14. Prongay AJ, Guo Z, Yao N, et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3- dioxopropyl]-3-[2(S)-[[[(1,1-dimethy lethyl)amino]carbonyl]amino]-3,3- dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S) -carboxamide (Sch 503034) II. Key steps in structure-based optimization. J Med Chem 2007; 50:2310-2318.
15. Seiwert SD, Andrews SW, Tan H, et al. Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. J Hepatol 2006; 44:S278.
16. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48:4784-4792.
17. McHutchison JG. 28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG-interferon-α-2a and Ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006; 131:250. Abstract DDW 2006.
18. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-1278.
19. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-1148.
20. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997.
21. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
22. Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77:3669-3679.
23. Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48:2260-2266.
24. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN-2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514.
25. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN-2061. J Biol Chem 2005; 280:36784- 36791.
26. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005; 49:4305-4314.
27. Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH-6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281:8205-8215.
28. Seiwert S, Hong J, Lim S, et al. In vitro synergistic antiviral activity of ITMN-191. Rev Antiviral Ther 2007; 1:56. Abstract 52.
29. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282:22619-22628.
30. Zeuzem S, Sarrazin C, Wagner F, et al. The HCV NS3 protease inhibitor SCH 503034 in combination with Peg-IFN alpha-2b in the treatment of HCV-1 Peg-IFN alpha-2b nonresponders: antiviral activity and HCV variant analysis. J Hepatology 2006; 44:S35.
31. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777.
32. Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN-2061 10.1128/JVI.78.14.7352-7359.2004. J Virol 2004; 78:7352-7359.
33. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41:832-835.
34. Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 2002; 147:1385-1406.
35. Lodrini S, Bagaglio S, Canducci F, et al. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 2003; 17:198-204.
36. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 2005; 75:528-537.
37. López-Labrador FX, Bracho MA, Berenguer M, et al. Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. J Viral Hepat 2006; 13:104-115.
38. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973.
39. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
40. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599.
41. Hall TA. Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. In Nucleic Acids Symposium Series 1999; 41:95-98.
42. Xia X, Xie Z. DAMBE: software package for data analysis in molecular biology and evolution. J Hered 2001; 92:371-373.
43. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res 2004; 14:1188-1190.
44. Korber B, Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992; 8:1549-1560.
45. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70:28-38.
46. Seiwert SD, Hon J, Lim SR, Wang T, Tan H, Blatt LM. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those lilkely to be achieved following clinical dosing. J Hepatol 2007; 46:S244-S245.
47. Filocamo G, Pacini L, Nardi C, et al. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric Sindbis viruses. J Virol 1999; 73:561-575.
48. Beyer BM, Zhang R, Hong Z, Madison V, Malcolm BA. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. Proteins 2001; 43:82-88.
49. Tong X, Guo Z, Wright-Minogue J, et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 2006; 45:1353-1361.
50. van Maarseveen NM, Wensing AMJ, Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007; 195:399-409.
51. Winters MA, Welles SL, Holodniy M. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. J Virol 2006; 80:4196-4199.
52. Franco S, Parera M, Aparicio E, Clotet B, Martínez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 2007; 45:899-910.
53. Combet C, Garnier N, Charavay C, et al. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 2007; 35:D363-366.
54. Hraber PT, Leach RW, Reilly LP, Thurmond J, Yusim K, Kuiken C. Los Alamos hepatitis C virus sequence and human immunology databases: an expanding resource for antiviral research. Antivir Chem Chemother 2007; 18:113-123.
55. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 43:631-639.
56. Abe K, Ikeda M, Dansako H, Naka K, Kato N. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res 2007; 125:88-97.